It's frustrating, and we all feel that. But selling shares (especially borrowed shares) has nothing to do with the efficacy of the molecule. The data so far is great. All of the data show greatly improved ctDNA, excellent safety, greater reductions in MRD, and improved or actionable biomarkers like PD-L1 (ICI).
Many on the board know my opinion that borrowing shares of a clinical stage medical company should not be allowed. Some have suggested that it is only due to financing, supplying liquidity, and arbitrage, and I agree that's probably part of it. The daily charts, which are not at all normal, say it's much more than that though. Take a look at the potential losses for sellers who borrow. It's huge. The potential gain is minuscule, so why do it? Do your own due diligence, but also just ask what motive a hedge fund, entity, or entities might have for keeping price low before a clinical stage biotech company goes into negotiations or approval. Thus, there could be other reasons, and they don't have anything to do with the efficacy of the molecule.
The only thing on the OTC that corrects this is more clinical trial data showing efficacy and regulatory approval, and then eventually the borrowed-share sellers go away, lose their shirts, their puppet masters tell them to get out because their motives have changed, or they move on to another target. If they are smart about it, they'll get out slowly, but they'll get out soon.
There has been choppy waters, but I believe that we are about to have smooth sailing on the open seas.
Hang in there. And thank you Dr J and team
KOKO&SLLH
Ramjet
Many on the board know my opinion that borrowing shares of a clinical stage medical company should not be allowed. Some have suggested that it is only due to financing, supplying liquidity, and arbitrage, and I agree that's probably part of it. The daily charts, which are not at all normal, say it's much more than that though. Take a look at the potential losses for sellers who borrow. It's huge. The potential gain is minuscule, so why do it? Do your own due diligence, but also just ask what motive a hedge fund, entity, or entities might have for keeping price low before a clinical stage biotech company goes into negotiations or approval. Thus, there could be other reasons, and they don't have anything to do with the efficacy of the molecule.
The only thing on the OTC that corrects this is more clinical trial data showing efficacy and regulatory approval, and then eventually the borrowed-share sellers go away, lose their shirts, their puppet masters tell them to get out because their motives have changed, or they move on to another target. If they are smart about it, they'll get out slowly, but they'll get out soon.
There has been choppy waters, but I believe that we are about to have smooth sailing on the open seas.
Hang in there. And thank you Dr J and team
KOKO&SLLH
Ramjet
5
